Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetazolamide/Dronabinol - Incannex Healthcare

Next Previous
Drug Profile

Acetazolamide/Dronabinol - Incannex Healthcare

Alternative Names: IHL-42X

Latest Information Update: 30 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incannex Healthcare
  • Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Sleep disorder therapies; Small molecules; Thiadiazoles; Thiazoles
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Sleep apnoea syndrome

Most Recent Events

  • 02 May 2024 Phase-II/III clinical trials in Sleep apnoea syndrome (Treatment-naive) in USA (PO) (NCT06146101)
  • 08 Sep 2023 Incannex Healthcare initiates enrolment in a phase I trial for Sleep apnoea syndrome (In volunteers) in Australia (PO) (NCT05857384)
  • 15 May 2023 Incannex Healthcare plans a phase I trial for Sleep apnoea syndrome(In volunteers) in June 2023 (NCT05857384)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top